Core Viewpoint - The biotechnology sector in China has made significant breakthroughs in the first half of 2025, driven by continuous policy support and technological innovation, particularly in innovative biopharmaceuticals, agricultural biotechnology, and life sciences [3][6]. Industry Overview - In the first half of 2025, the biotechnology sector achieved notable advancements, with key areas such as innovative biopharmaceuticals, agricultural biotechnology, and life sciences showing outstanding performance [6]. - The integration of AI with biotechnology is emerging as a new trend, enhancing research efficiency and accelerating industrialization [6]. - The internationalization of innovative drugs continues to thrive, with a total disclosed cooperation amount reaching $50.88 billion in the first half of 2025, maintaining the momentum from 2024 [6]. Investment Dynamics - In Q2 2025, there were 136 financing cases in the biotechnology sector across China, with a disclosed financing scale of 4.061 billion yuan [18]. - The biopharmaceutical sector attracted the most investor interest, with 62 financing cases totaling 3.007 billion yuan, focusing on cell therapy and antibody drugs [18]. - Early-stage financing (angel to A-round) accounted for 66.18% of the total cases, indicating a preference for smaller, earlier investments in high-tech potential startups [18][23]. Key Financing Events - Notable financing events in Q2 2025 included: - Jiangyin Pharmaceutical raised nearly $50 million in B2 round financing for its novel siRNA therapy [11]. - Chuangxin International completed nearly 100 million yuan in B round financing to accelerate organoid technology development [12]. - LiDe Health secured nearly 100 million yuan in angel round financing for life science instruments and reagents [15] [28]. Policy Environment - Continuous policy support is evident, with the Ministry of Agriculture and Rural Affairs issuing measures to enhance the management of crop varieties, promoting the introduction of high-yield and disease-resistant crops [9][13]. - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, including the encouragement of commercial health insurance to establish investment funds for innovative drug development [9][14]. Trends in Biopharmaceuticals - The biopharmaceutical sector is increasingly focusing on innovative veterinary drugs, with a shift towards alternatives to antibiotics, such as vaccines and microbial preparations, to address antibiotic resistance [30][31]. - The rise of pet healthcare has spurred investment and innovation in veterinary pharmaceuticals, with the pet medical market reaching 94 billion yuan in 2024 [34]. Representative Company - Wuhan Greennong Biotechnology Co., Ltd. specializes in the research and industrialization of phage preparations, focusing on animal health and food safety [44][47]. - The company has received multiple certifications and has developed solutions targeting various bacterial diseases in livestock, significantly reducing disease risks [44][48].

Investment Rating - The report indicates a positive investment outlook for the biotechnology sector, highlighting significant growth potential driven by policy support and technological innovation [6][9][17]. Core Insights - The biotechnology industry has made notable advancements in the first half of 2025, particularly in innovative biopharmaceuticals, agricultural biotechnology, and life sciences, with AI integration enhancing research efficiency and commercialization [6][7]. - The total disclosed collaboration amount in the first half of 2025 reached $50.88 billion, continuing the trend from 2024, which saw a record high of $52.26 billion in outbound business development transactions [6]. - Policies are actively promoting the development of agricultural biotechnology, with measures introduced to accelerate the introduction of high-yield and disease-resistant crop varieties [6][12]. Summary by Sections Industry Overview - The biotechnology sector is experiencing breakthroughs due to continuous policy support and technological advancements, with AI playing a crucial role in enhancing research and development efficiency [6][7]. - The integration of innovative drugs into international markets is thriving, with improved payment factors for innovative drugs under commercial insurance [6]. Policy Developments - Various policies have been introduced to support the innovative drug sector, including measures to optimize clinical trial approvals and encourage the establishment of investment funds for innovative drug development [9][15][17]. - The Ministry of Agriculture has issued measures to strengthen the management of crop varieties, aiming to enrich breeding resources [12][17]. Investment Trends - In Q2 2025, the biotechnology sector saw 136 financing cases totaling approximately 4.06 billion yuan, with a focus on biopharmaceuticals, agricultural biotechnology, and life sciences [23][27]. - Early-stage investments (seed to A rounds) accounted for 66.18% of financing cases, indicating a preference for smaller, earlier investments in high-potential startups [23][28]. Key Financing Events - Significant financing events include: - AusperBio raised $50 million in a B+ round for its RNA drug development [35]. - LiDe Health completed nearly 100 million yuan in angel financing for life science instruments [35]. - JingYin Pharmaceutical secured nearly $5 million in a B2 round for its siRNA therapy [35]. Sector-Specific Insights - The report highlights the growing importance of biopharmaceuticals, particularly in cell therapy and antibody drugs, as key areas attracting investor interest [23][33]. - The agricultural biotechnology sector is also gaining traction, with significant investments in synthetic biology and veterinary pharmaceuticals [23][33].

Core Viewpoint - The article discusses the significant transformation in the veterinary medicine industry in China, driven by the reduction and replacement of antibiotics in animal husbandry, alongside the rising demand for pet healthcare products, highlighting investment opportunities in the biological veterinary drug sector [3][4][5]. Group 1: Antibiotic Reduction and Replacement - The veterinary medicine industry is crucial for ensuring animal health and disease prevention, which in turn stabilizes the supply of meat and eggs [4]. - Historically, the industry relied heavily on antibiotics, leading to increased antibiotic resistance and environmental contamination [4][5]. - Since 2020, China has implemented strict regulations to phase out growth-promoting antibiotics, promoting the development of alternative products [5][6]. Group 2: Current Status of Biological Veterinary Drugs - Biological veterinary drugs, including vaccines and microbial preparations, are becoming essential for sustainable animal husbandry and food safety [6][7]. - Vaccines are the most significant category within biological veterinary drugs, preventing infectious diseases and reducing the need for antibiotics [6][7]. - The development of innovative veterinary drugs in China has lagged behind due to market preferences for cheaper, traditional solutions [8][9]. Group 3: Investment Dynamics - The rise of pet culture has led to increased investment in the veterinary drug sector, particularly in pet healthcare products [9][12]. - The Chinese pet medical market is projected to reach 94 billion yuan by 2024, indicating a growing focus on pet pharmaceuticals [9]. - Recent financing activities in the biological veterinary drug sector have primarily occurred in early to mid-stage investments, with significant interest in pet vaccines and alternative antibiotic products [12][13].